CoChat
Sign Up
Cited by 96Renin-Angiotensin System StudiesCoagulation, Bradykinin, Polyphosphates, and AngioedemaEicosanoids and Hypertension Pharmacology

Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review

Open access
Laghlam, Driss, Jozwiak, Mathieu, Nguyen, Lee S.·2021·Cells
DOI 10.3390/cells10071767PMC PMC8303450
Open this paper in CoChat — free accountOpen PDF

Abstract

The renin–angiotensin system (RAS) has long been described in the field of cardiovascular physiology as the main player in blood pressure homeostasis. However, other effects have since been described, and include proliferation, fibrosis, and inflammation. To illustrate the immunomodulatory properties of the RAS, we chose three distinct fields in which RAS may play a critical role and be the subject of specific treatments. In oncology, RAS hyperactivation has been associated with tumor migration, survival, cell proliferation, and angiogenesis; preliminary data showed promise of the benefit of RAS blockers in patients treated for certain types of cancer. In intensive care medicine, vasoplegic shock has been associated with severe macro- and microcirculatory imbalance. A relative insufficiency in angiotensin II (AngII) was associated to lethal outcomes and synthetic AngII has been suggested as a specific treatment in these cases. Finally, in solid organ transplantation, both AngI and AngII have been associated with increased rejection events, with a regional specificity in the RAS activity. These elements emphasize the complexity of the direct and indirect interactions of RAS with immunomodulatory pathways and warrant further research in the field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells10071767

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 188

  1. [1]de Gasparo M. Catt K.J. Inagami T. Wright J.W. Unger T. International union of pharmacology. XXIII. The angiotensin II receptors Pharmacol. Rev. 2000 52 415 472 10977869
  2. [2]Paz Ocaranza M. Riquelme J.A. García L. Jalil J.E. Chiong M. Santos R.A.S. Lavandero S. Counter-regulatory renin-angiotensin system in cardiovascular disease Nat. Rev. Cardiol. 2020 17 116 129 10.1038/s41569-019-0244-8 31427727 PMC7097090 · DOI · Paper page
  3. [3]Passos-Silva D.G. Verano-Braga T. Santos R.A. Angiotensin-(1–7): Beyond the cardio-renal actions Clin. Sci. (Lond.) 2013 124 443 456 10.1042/CS20120461 23249272 · DOI
  4. [4]Ocaranza M.P. Moya J. Barrientos V. Alzamora R. Hevia D. Morales C. Pinto M. Escudero N. García L. Novoa U. Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis J. Hypertens. 2014 32 771 783 10.1097/HJH.0000000000000094 24463937 · DOI
  5. [5]Drummond G.R. Vinh A. Guzik T.J. Sobey C.G. Immune mechanisms of hypertension Nat. Rev. Immunol. 2019 19 517 532 10.1038/s41577-019-0160-5 30992524 · DOI
  6. [6]Mikolajczyk T.P. Guzik T.J. Adaptive Immunity in Hypertension Curr. Hypertens. Rep. 2019 21 68 10.1007/s11906-019-0971-6 31321561 PMC6647517 · DOI
  7. [7]Xiao L. do Carmo L.S. Foss J.D. Chen W. Harrison D.G. Sympathetic Enhancement of Memory T-Cell Homing and Hypertension Sensitization Circ. Res. 2020 126 708 721 10.1161/CIRCRESAHA.119.314758 31928179 PMC8253247 · DOI
  8. [8]Marvar P.J. Harrison D.G. Stress-dependent hypertension and the role of T lymphocytes Exp. Physiol. 2012 97 1161 1167 10.1113/expphysiol.2011.061507 22941978 PMC4654775 · DOI
  9. [9]Zhao J.V. Schooling C.M. Leung G.M. Using genetics to understand the role of antihypertensive drugs modulating angiotensin-converting enzyme in immune function and inflammation Br. J. Clin. Pharmacol. 2021 87 1839 1846 10.1111/bcp.14572 33025652 PMC7675404 · DOI
  10. [10]Qin X.Y. Zhang Y.L. Chi Y.F. Yan B. Zeng X.J. Li H.H. Liu Y. Angiotensin II Regulates Th1 T Cell Differentiation Through Angiotensin II Type 1 Receptor-PKA-Mediated Activation of Proteasome Cell. Physiol. Biochem. 2018 45 1366 1376 10.1159/000487562 29462804 · DOI
  11. [11]Hunyady L. Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II Mol. Endocrinol. 2006 20 953 970 10.1210/me.2004-0536 16141358 · DOI · Paper page
  12. [12]Balakumar P. Jagadeesh G. A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology Cell. Signal. 2014 26 2147 2160 10.1016/j.cellsig.2014.06.011 25007996 · DOI · Paper page
  13. [13]Mehta P.K. Griendling K.K. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system Am. J. Physiol. Cell Physiol. 2007 292 C82 C97 10.1152/ajpcell.00287.2006 16870827 · DOI · Paper page
  14. [14]Anavekar N.S. Solomon S.D. Angiotensin II receptor blockade and ventricular remodelling J. Renin Angiotensin Aldosterone Syst. 2005 6 43 48 10.3317/jraas.2005.006 16088851 · DOI
  15. [15]Suzuki K. Han G.D. Miyauchi N. Hashimoto T. Nakatsue T. Fujioka Y. Koike H. Shimizu F. Kawachi H. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall Am. J. Pathol. 2007 170 1841 1853 10.2353/ajpath.2007.060484 17525253 PMC1899458 · DOI
  16. [16]Niu M.J. Yang J.K. Lin S.S. Ji X.J. Guo L.M. Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice Endocrine 2008 34 56 61 10.1007/s12020-008-9110-x 18956256 · DOI
  17. [17]Patel V.B. Mori J. McLean B.A. Basu R. Das S.K. Ramprasath T. Parajuli N. Penninger J.M. Grant M.B. Lopaschuk G.D. ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity Diabetes 2016 65 85 95 10.2337/db15-0399 26224885 PMC4686955 · DOI
  18. [18]Coppo M. Bandinelli M. Chiostri M. Poggesi L. Boddi M. T-Lymphocyte-Based Renin Angiotensin System in Obesity Am. J. Med. Sci. 2019 358 51 58 10.1016/j.amjms.2019.03.008 31084908 · DOI
  19. [19]Bindom S.M. Hans C.P. Xia H. Boulares A.H. Lazartigues E. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice Diabetes 2010 59 2540 2548 10.2337/db09-0782 20660625 PMC3279528 · DOI
  20. [20]Osterreicher C.H. Taura K. De Minicis S. Seki E. Penz-Osterreicher M. Kodama Y. Kluwe J. Schuster M. Oudit G.Y. Penninger J.M. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice Hepatology 2009 50 929 938 10.1002/hep.23104 19650157 PMC4734904 · DOI
  21. [21]Cao X. Yang F. Shi T. Yuan M. Xin Z. Xie R. Li S. Li H. Yang J.K. Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis Sci. Rep. 2016 6 21592 10.1038/srep21592 26883384 PMC4756304 · DOI
  22. [22]Munoz M.C. Giani J.F. Dominici F.P. Angiotensin-(1–7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas Regul. Pept. 2010 161 1 7 10.1016/j.regpep.2010.02.001 20188769 · DOI
  23. [23]Feltenberger J.D. Andrade J.M. Paraiso A. Barros L.O. Filho A.B. Sinisterra R.D. Sousa F.B. Guimaraes A.L. de Paula A.M. Campagnole-Santos M.J. Oral formulation of angiotensin-(1–7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice Hypertension 2013 62 324 330 10.1161/HYPERTENSIONAHA.111.00919 23753417 · DOI
  24. [24]Santos S.H. Andrade J.M. Fernandes L.R. Sinisterra R.D. Sousa F.B. Feltenberger J.D. Alvarez-Leite J.I. Santos R.A. Oral Angiotensin-(1–7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-kappaB in rats fed with high-fat diet Peptides 2013 46 47 52 10.1016/j.peptides.2013.05.010 23714175 · DOI
  25. [25]Santos S.H. Fernandes L.R. Pereira C.S. Guimaraes A.L. de Paula A.M. Campagnole-Santos M.J. Alvarez-Leite J.I. Bader M. Santos R.A. Increased circulating angiotensin-(1–7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet Regul. Pept. 2012 178 64 70 10.1016/j.regpep.2012.06.009 22749992 · DOI
  26. [26]Liu C. Lv X.H. Li H.X. Cao X. Zhang F. Wang L. Yu M. Yang J.K. Angiotensin-(1–7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes Acta Diabetol. 2012 49 291 299 10.1007/s00592-011-0348-z 22042130 · DOI
  27. [27]Santos S.H. Braga J.F. Mario E.G. Porto L.C. Rodrigues-Machado Mda G. Murari A. Botion L.M. Alenina N. Bader M. Santos R.A. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1–7) Arterioscler. Thromb. Vasc. Biol. 2010 30 953 961 10.1161/ATVBAHA.109.200493 20203301 · DOI
  28. [28]Santos S.H. Fernandes L.R. Mario E.G. Ferreira A.V. Porto L.C. Alvarez-Leite J.I. Botion L.M. Bader M. Alenina N. Santos R.A. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism Diabetes 2008 57 340 347 10.2337/db07-0953 18025412 · DOI
  29. [29]Saiki A. Ohira M. Endo K. Koide N. Oyama T. Murano T. Watanabe H. Miyashita Y. Shirai K. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus Metab. Clin. Exp. 2009 58 708 713 10.1016/j.metabol.2009.01.013 19375596 · DOI
  30. [30]Wei Y. Clark S.E. Morris E.M. Thyfault J.P. Uptergrove G.M. Whaley-Connell A.T. Ferrario C.M. Sowers J.R. Ibdah J.A. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats J. Hepatol. 2008 49 417 428 10.1016/j.jhep.2008.03.018 18486983 PMC2683586 · DOI
  31. [31]Wei Y. Sowers J.R. Nistala R. Gong H. Uptergrove G.M. Clark S.E. Morris E.M. Szary N. Manrique C. Stump C.S. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells J. Biol. Chem. 2006 281 35137 35146 10.1074/jbc.M601320200 16982630 · DOI
  32. [32]Chou C.L. Lin H. Chen J.S. Fang T.C. Renin inhibition improves metabolic syndrome, and reduces angiotensin II levels and oxidative stress in visceral fat tissues in fructose-fed rats PLoS ONE 2017 12 e0180712 10.1371/journal.pone.0180712 28700686 PMC5507254 · DOI
  33. [33]Ino K. Shibata K. Kajiyama H. Yamamoto E. Nagasaka T. Nawa A. Nomura S. Kikkawa F. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival Br. J. Cancer 2006 94 552 560 10.1038/sj.bjc.6602961 16434990 PMC2361172 · DOI
  34. [34]Delforce S.J. Lumbers E.R. Corbisier de Meaultsart C. Wang Y. Proietto A. Otton G. Scurry J. Verrills N.M. Scott R.J. Pringle K.G. Expression of renin-angiotensin system (RAS) components in endometrial cancer Endocr. Connect. 2017 6 9 19 10.1530/EC-16-0082 27956412 PMC5302162 · DOI
  35. [35]Acconcia F. The Network of Angiotensin Receptors in Breast Cancer Cells 2020 9 1336 10.3390/cells9061336 PMC7349848 32471115 · DOI
  36. [36]Fujimoto Y. Sasaki T. Tsuchida A. Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist FEBS Lett. 2001 495 197 200 10.1016/S0014-5793(01)02377-8 11334891 · DOI
  37. [37]Fujita M. Hayashi I. Yamashina S. Fukamizu A. Itoman M. Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth Carcinogenesis 2005 26 271 279 10.1093/carcin/bgh324 15637093 · DOI
  38. [38]Cheng N. Bai X. Shu Y. Ahmad O. Shen P. Targeting tumor-associated macrophages as an antitumor strategy Biochem. Pharmacol. 2021 183 114354 10.1016/j.bcp.2020.114354 33279498 · DOI
  39. [39]Tharaux P.L. Chatziantoniou C. Fakhouri F. Dussaule J.C. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway Hypertension 2000 36 330 336 10.1161/01.HYP.36.3.330 10988260 · DOI · Paper page
  40. [40]Davis J.E. Xie X. Guo J. Huang W. Chu W.M. Huang S. Teng Y. Wu G. ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling Oncotarget 2016 7 39834 39845 10.18632/oncotarget.9405 27213581 PMC5129974 · DOI
  41. [41]Greco S. Muscella A. Elia M.G. Salvatore P. Storelli C. Mazzotta A. Manca C. Marsigliante S. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells J. Cell. Physiol. 2003 196 370 377 10.1002/jcp.10313 12811831 · DOI
  42. [42]Uemura H. Ishiguro H. Nakaigawa N. Nagashima Y. Miyoshi Y. Fujinami K. Sakaguchi A. Kubota Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor Mol. Cancer Ther. 2003 2 1139 1147 14617787
  43. [43]Fujiyama S. Matsubara H. Nozawa Y. Maruyama K. Mori Y. Tsutsumi Y. Masaki H. Uchiyama Y. Koyama Y. Nose A. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation Circ. Res. 2001 88 22 29 10.1161/01.RES.88.1.22 11139469 · DOI
  44. [44]Anandanadesan R. Gong Q. Chipitsyna G. Witkiewicz A. Yeo C.J. Arafat H.A. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling J. Gastrointest. Surg. 2008 12 57 66 10.1007/s11605-007-0403-9 18026817 · DOI
  45. [45]Kosugi M. Miyajima A. Kikuchi E. Kosaka T. Horiguchi Y. Murai M. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer Hum. Cell 2007 20 1 9 10.1111/j.1749-0774.2007.00025.x 17506771 · DOI
  46. [46]Fan F. Tian C. Tao L. Wu H. Liu Z. Shen C. Jiang G. Lu Y. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway Biomed. Pharmacother. 2016 83 704 711 10.1016/j.biopha.2016.07.039 27470571 · DOI
  47. [47]Suganuma T. Ino K. Shibata K. Kajiyama H. Nagasaka T. Mizutani S. Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination Clin. Cancer Res. 2005 11 2686 2694 10.1158/1078-0432.CCR-04-1946 15814650 · DOI
  48. [48]Zhao Y. Wang H. Li X. Cao M. Lu H. Meng Q. Pang H. Li H. Nadolny C. Dong X. Ang II-AT1R increases cell migration through PI3K/AKT and NF-κB pathways in breast cancer J. Cell. Physiol. 2014 229 1855 1862 10.1002/jcp.24639 24692224 · DOI
  49. [49]Bose S.K. Gibson W. Giri S. Nath N. Donald C.D. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor Prostate 2009 69 1334 1342 10.1002/pros.20980 19517575 · DOI
  50. [50]Kinoshita J. Fushida S. Harada S. Yagi Y. Fujita H. Kinami S. Ninomiya I. Fujimura T. Kayahara M. Yashiro M. Local angiotensin II-generation in human gastric cancer: Correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin Int. J. Oncol. 2009 34 1573 1582 10.3892/ijo_00000287 19424575 · DOI
  51. [51]Ohashi H. Takagi H. Oh H. Suzuma K. Suzuma I. Miyamoto N. Uemura A. Watanabe D. Murakami T. Sugaya T. Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity Circ. Res. 2004 94 785 793 10.1161/01.RES.0000121103.03275.EC 14963002 · DOI
  52. [52]Chauhan V.P. Martin J.D. Liu H. Lacorre D.A. Jain S.R. Kozin S.V. Stylianopoulos T. Mousa A.S. Han X. Adstamongkonkul P. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels Nat. Commun. 2013 4 2516 10.1038/ncomms3516 24084631 PMC3806395 · DOI · Paper page
  53. [53]Lever A.F. Hole D.J. Gillis C.R. McCallum I.R. McInnes G.T. MacKinnon P.L. Meredith P.A. Murray L.S. Reid J.L. Robertson J.W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998 352 179 184 10.1016/S0140-6736(98)03228-0 9683206 · DOI
  54. [54]Friis S. Sørensen H.T. Mellemkjaer L. McLaughlin J.K. Nielsen G.L. Blot W.J. Olsen J.H. Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark Cancer 2001 92 2462 2470 10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L 11745304 · DOI
  55. [55]Sipahi I. Debanne S.M. Rowland D.Y. Simon D.I. Fang J.C. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials Lancet Oncol. 2010 11 627 636 10.1016/S1470-2045(10)70106-6 20542468 PMC4070221 · DOI
  56. [56]Shen J. Huang Y.M. Wang M. Hong X.Z. Song X.N. Zou X. Pan Y.H. Ling W. Zhu M.H. Zhang X.X. Renin-angiotensin system blockade for the risk of cancer and death J. Renin Angiotensin Aldosterone Syst. 2016 17 10.1177/1470320316656679 PMC5843874 27402638 · DOI
  57. [57]Yoon C. Yang H.S. Jeon I. Chang Y. Park S.M. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: A meta-analysis of observational studies CMAJ 2011 183 E1073 E1084 10.1503/cmaj.101497 21876027 PMC3185099 · DOI
  58. [58]Dai Y.N. Wang J.H. Zhu J.Z. Lin J.Q. Yu C.H. Li Y.M. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: A systematic review and meta-analysis Cancer Causes Control. 2015 26 1245 1255 10.1007/s10552-015-0617-1 26081426 · DOI
  59. [59]Cheung K.S. Chan E.W. Seto W.K. Wong I.C.K. Leung W.K. ACE (Angiotensin-Converting Enzyme) Inhibitors/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk: A Territory-Wide Study With Propensity Score Analysis Hypertension 2020 76 968 975 10.1161/HYPERTENSIONAHA.120.15317 32623923 · DOI
  60. [60]Christian J.B. Lapane K.L. Hume A.L. Eaton C.B. Weinstock M.A. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial J. Natl. Cancer Inst. 2008 100 1223 1232 10.1093/jnci/djn262 18728281 · DOI
  61. [61]Mao Y. Xu X. Wang X. Zheng X. Xie L. Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer? Oncotarget 2016 7 6765 6773 10.18632/oncotarget.6837 26760503 PMC4872747 · DOI
  62. [62]Hagberg K.W. Sahasrabuddhe V.V. McGlynn K.A. Jick S.S. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink Pharmacotherapy 2016 36 187 195 10.1002/phar.1704 26846893 PMC5808860 · DOI
  63. [63]Qian Y.F. Xu W.G. Wu J. Angiotensin receptor blockers and breast cancer risk: A meta-analysis Panminerva Med. 2017 59 269 273 10.23736/S0031-0808.16.03211-0 27631721 · DOI
  64. [64]Ni H. Rui Q. Zhu X. Yu Z. Gao R. Liu H. Antihypertensive drug use and breast cancer risk: A meta-analysis of observational studies Oncotarget 2017 8 62545 62560 10.18632/oncotarget.19117 28977968 PMC5617528 · DOI
  65. [65]Xie Y. Xu P. Wang M. Zheng Y. Tian T. Yang S. Deng Y. Wu Y. Zhai Z. Hao Q. Antihypertensive medications are associated with the risk of kidney and bladder cancer: A systematic review and meta-analysis Aging (Albany N. Y.) 2020 12 1545 1562 10.18632/aging.102699 PMC7053620 31968309 · DOI
  66. [66]Trifilieff A. Da Silva A. Gies J.P. Kinins and respiratory tract diseases Eur. Respir. J. 1993 6 576 587 8387934
  67. [67]Muñoz M. Coveñas R. Involvement of substance P and the NK-1 receptor in human pathology Amino Acids 2014 46 1727 1750 10.1007/s00726-014-1736-9 24705689 · DOI
  68. [68]Hicks B.M. Filion K.B. Yin H. Sakr L. Udell J.A. Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: Population based cohort study BMJ 2018 363 k4209 10.1136/bmj.k4209 30355745 PMC6199558 · DOI
  69. [69]Lin S.Y. Lin C.L. Lin C.C. Hsu W.H. Lin C.D. Wang I.K. Hsu C.Y. Kao C.H. Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer-A Nationwide, Population-Based, Propensity Score-Matched Cohort Study Cancers 2020 12 747 10.3390/cancers12030747 PMC7140054 32245239 · DOI
  70. [70]Cardinale D. Colombo A. Sandri M.T. Lamantia G. Colombo N. Civelli M. Martinelli G. Veglia F. Fiorentini C. Cipolla C.M. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 2006 114 2474 2481 10.1161/CIRCULATIONAHA.106.635144 17101852 · DOI
  71. [71]Guglin M. Krischer J. Tamura R. Fink A. Bello-Matricaria L. McCaskill-Stevens W. Munster P.N. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients with Breast Cancer J. Am. Coll. Cardiol. 2019 73 2859 2868 10.1016/j.jacc.2019.03.495 31171092 PMC6557296 · DOI
  72. [72]Wittayanukorn S. Qian J. Westrick S.C. Billor N. Johnson B. Hansen R.A. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults with Breast Cancer Am. J. Clin. Oncol. 2018 41 909 918 10.1097/COC.0000000000000389 28537988 · DOI
  73. [73]Pituskin E. Mackey J.R. Koshman S. Jassal D. Pitz M. Haykowsky M.J. Pagano J.J. Chow K. Thompson R.B. Vos L.J. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity J. Clin. Oncol. 2017 35 870 877 10.1200/JCO.2016.68.7830 27893331 · DOI
  74. [74]Moey M.Y.Y. Liles D.K. Carabello B.A. Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: An institutional retrospective study Cardiooncology 2019 5 9 10.1186/s40959-019-0043-8 32154015 PMC7048102 · DOI
  75. [75]Gulati G. Heck S.L. Ree A.H. Hoffmann P. Schulz-Menger J. Fagerland M.W. Gravdehaug B. von Knobelsdorff-Brenkenhoff F. Bratland Å. Storås T.H. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Eur. Heart J. 2016 37 1671 1680 10.1093/eurheartj/ehw022 26903532 PMC4887703 · DOI
  76. [76]Pinter M. Kwanten W.J. Jain R.K. Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events Clin. Cancer Res. 2018 24 3803 3812 10.1158/1078-0432.CCR-18-0236 29610292 PMC6095804 · DOI
  77. [77]Ronquist G. Frithz G. Wang Y.H. Lindeborg T. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer Scand. J. Urol. Nephrol. 2009 43 32 36 10.1080/00365590802468875 18932051 · DOI
  78. [78]Yoshiji H. Noguchi R. Ikenaka Y. Kaji K. Aihara Y. Yamazaki M. Yamao J. Toyohara M. Mitoro A. Sawai M. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial Oncol. Rep. 2011 26 1547 1553 10.3892/or.2011.1433 21874260 · DOI
  79. [79]Song T. Choi C.H. Kim M.K. Kim M.L. Yun B.S. Seong S.J. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis Eur. J. Cancer Prev. 2017 26 78 85 10.1097/CEJ.0000000000000269 27158979 · DOI
  80. [80]Li X.Y. Sun J.F. Hu S.Q. The renin-angiotensin system blockers as adjunctive therapy for cancer: A meta-analysis of survival outcome Eur. Rev. Med. Pharmacol. Sci. 2017 21 1375 1383 28387887
  81. [81]Morris Z.S. Saha S. Magnuson W.J. Morris B.A. Borkenhagen J.F. Ching A. Hirose G. McMurry V. Francis D.M. Harari P.M. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers Cancer 2016 122 2487 2495 10.1002/cncr.30079 27203227 PMC4998053 · DOI
  82. [82]Ozawa T. Hashiguchi Y. Yagi T. Fukushima Y. Shimada R. Hayama T. Tsuchiya T. Nozawa K. Iinuma H. Ishihara S. Angiotensin I-converting enzyme inhibitors/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers Int. J. Colorectal Dis. 2019 34 1731 1739 10.1007/s00384-019-03379-y 31478086 · DOI
  83. [83]Zhou Q. Chen D.S. Xin L. Zhou L.Q. Zhang H.T. Liu L. Yuan Y.W. Li S.H. The renin-angiotensin system blockers and survival in digestive system malignancies: A systematic review and meta-analysis Medicine (Baltimore) 2020 99 e19075 10.1097/MD.0000000000019075 32049809 PMC7035076 · DOI
  84. [84]Santala E.E.E. Murto M.O. Artama M. Pukkala E. Visvanathan K. Murtola T.J. Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland Cancer Epidemiol. Biomark. Prev. 2020 29 2376 2382 10.1158/1055-9965.EPI-20-0711 32917663 · DOI
  85. [85]Alashkham A. Paterson C. Windsor P. Struthers A. Rauchhaus P. Nabi G. The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs) Clin. Genitourin. Cancer 2016 14 398 405 10.1016/j.clgc.2016.03.009 27053500 · DOI
  86. [86]Asgharzadeh F. Hashemzehi M. Moradi-Marjaneh R. Hassanian S.M. Ferns G.A. Khazaei M. Avan A. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis Life Sci. 2020 242 117181 10.1016/j.lfs.2019.117181 31863771 · DOI
  87. [87]Blute M.L. Jr. Rushmer T.J. Shi F. Fuller B.J. Abel E.J. Jarrard D.F. Downs T.M. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer J. Urol. 2015 194 1214 1219 10.1016/j.juro.2015.05.104 26173101 PMC8366568 · DOI
  88. [88]Yoshida T. Kinoshita H. Fukui K. Matsuzaki T. Yoshida K. Mishima T. Yanishi M. Komai Y. Sugi M. Inoue T. Prognostic Impact of Renin-Angiotensin Inhibitors in Patients with Bladder Cancer Undergoing Radical Cystectomy Ann. Surg. Oncol. 2017 24 823 831 10.1245/s10434-016-5534-3 27730369 · DOI
  89. [89]Santala E.E.E. Kotsar A. Veitonmäki T. Tammela T.L.J. Murtola T.J. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland Scand. J. Urol. 2019 53 185 192 10.1080/21681805.2019.1634147 31250699 · DOI
  90. [90]Menter A.R. Carroll N.M. Sakoda L.C. Delate T. Hornbrook M.C. Jain R.K. Kushi L.H. Quinn V.P. Ritzwoller D.P. Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer Clin. Lung Cancer 2017 18 189 197.e3 10.1016/j.cllc.2016.07.008 27637408 PMC5424707 · DOI
  91. [91]Wilop S. von Hobe S. Crysandt M. Esser A. Osieka R. Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy J. Cancer Res. Clin. Oncol. 2009 135 1429 1435 10.1007/s00432-009-0587-3 19399518 PMC12160257 · DOI
  92. [92]Medjebar S. Truntzer C. Perrichet A. Limagne E. Fumet J.D. Richard C. Elkrief A. Routy B. Rébé C. Ghiringhelli F. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers Oncoimmunology 2020 9 1836766 10.1080/2162402X.2020.1836766 33178495 PMC7595630 · DOI
  93. [93]Russell J.A. Vasopressor therapy in critically ill patients with shock Intensive Care Med. 2019 45 1503 1517 10.1007/s00134-019-05801-z 31646370 · DOI
  94. [94]Correa T.D. Takala J. Jakob S.M. Angiotensin II in septic shock Crit. Care 2015 19 98 10.1186/s13054-015-0802-3 25886853 PMC4360936 · DOI
  95. [95]Hilgenfeldt U. Kienapfel G. Kellermann W. Schott R. Schmidt M. Renin-angiotensin system in sepsis Clin. Exp. Hypertens. A 1987 9 1493 1504 10.3109/10641968709158998 2820628 · DOI
  96. [96]Cumming A.D. Driedger A.A. McDonald J.W. Lindsay R.M. Solez K. Linton A.L. Vasoactive hormones in the renal response to systemic sepsis Am. J. Kidney Dis. 1988 11 23 32 10.1016/S0272-6386(88)80170-7 3276170 · DOI
  97. [97]Dunn C.W. Horton J.W. Role of angiotensin II in neonatal sepsis Circ. Shock 1993 40 144 150 8508519
  98. [98]Rolih C.A. Ober K.P. The endocrine response to critical illness Med. Clin. N. Am. 1995 79 211 224 10.1016/S0025-7125(16)30093-1 7808093 · DOI
  99. [99]Boldt J. Papsdorf M. Kumle B. Piper S. Hempelmann G. Influence of angiotensin-converting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill Crit. Care Med. 1998 26 1663 1670 10.1097/00003246-199810000-00018 9781723 · DOI
  100. [100]Aneman A. Bengtsson J. Snygg J. Holm M. Pettersson A. Fandriks L. Differentiation of the peptidergic vasoregulatory response to standardized splanchnic hypoperfusion by acute hypovolaemia or sepsis in anaesthetized pigs Acta Physiol. Scand. 1999 166 293 300 10.1046/j.1365-201x.1999.00574.x 10468666 · DOI
  101. [101]Bucher M. Ittner K.P. Hobbhahn J. Taeger K. Kurtz A. Downregulation of angiotensin II type 1 receptors during sepsis Hypertension 2001 38 177 182 10.1161/01.HYP.38.2.177 11509472 · DOI
  102. [102]du Cheyron D. Lesage A. Daubin C. Ramakers M. Charbonneau P. Hyperreninemic hypoaldosteronism: A possible etiological factor of septic shock-induced acute renal failure Intensive Care Med. 2003 29 1703 1709 10.1007/s00134-003-1986-6 14551679 · DOI
  103. [103]Schrier R.W. Wang W. Acute renal failure and sepsis N. Engl. J. Med. 2004 351 159 169 10.1056/NEJMra032401 15247356 · DOI
  104. [104]Tamion F. Le Cam-Duchez V. Menard J.F. Girault C. Coquerel A. Bonmarchand G. Erythropoietin and renin as biological markers in critically ill patients Crit. Care 2004 8 R328 R335 10.1186/cc2902 15469576 PMC1065015 · DOI
  105. [106]Schaller M.D. Waeber B. Nussberger J. Brunner H.R. Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia Am. J. Physiol. 1985 249 H1086 H1092 10.1152/ajpheart.1985.249.6.H1086 3907375 · DOI
  106. [107]Bucher M. Hobbhahn J. Kurtz A. Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis Crit. Care Med. 2001 29 1750 1755 10.1097/00003246-200109000-00016 11546977 · DOI
  107. [108]Imai Y. Kuba K. Rao S. Huan Y. Guo F. Guan B. Yang P. Sarao R. Wada T. Leong-Poi H. Angiotensin-converting enzyme 2 protects from severe acute lung failure Nature 2005 436 112 116 10.1038/nature03712 16001071 PMC7094998 · DOI · Paper page
  108. [109]Lund D.D. Brooks R.M. Faraci F.M. Heistad D.D. Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice Am. J. Physiol. Heart Circ. Physiol. 2007 293 H3726 H3731 10.1152/ajpheart.01116.2007 17965276 · DOI
  109. [110]Wan L. Langenberg C. Bellomo R. May C.N. Angiotensin II in experimental hyperdynamic sepsis Crit. Care 2009 13 R190 10.1186/cc8185 19948019 PMC2811902 · DOI
  110. [111]May C.N. Ishikawa K. Wan L. Williams J. Wellard R.M. Pell G.S. Jackson G.D. Bellomo R. Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion Intensive Care Med. 2012 38 886 893 10.1007/s00134-012-2487-2 22302028 · DOI
  111. [112]Mederle K. Schweda F. Kattler V. Doblinger E. Miyata K. Hocherl K. Oike Y. Castrop H. The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension Crit. Care 2013 17 R130 10.1186/cc12809 23844607 PMC4056110 · DOI
  112. [113]Klein N. Gembardt F. Supe S. Kaestle S.M. Nickles H. Erfinanda L. Lei X. Yin J. Wang L. Mertens M. Angiotensin-(1–7) protects from experimental acute lung injury Crit. Care Med. 2013 41 e334 e343 10.1097/CCM.0b013e31828a6688 23949470 · DOI
  113. [114]Basso N. Terragno N.A. History about the discovery of the renin-angiotensin system Hypertension 2001 38 1246 1249 10.1161/hy1201.101214 11751697 · DOI
  114. [115]Adembri C. Kastamoniti E. Bertolozzi I. Vanni S. Dorigo W. Coppo M. Pratesi C. De Gaudio A.R. Gensini G.F. Modesti P.A. Pulmonary injury follows systemic inflammatory reaction in infrarenal aortic surgery Crit. Care Med. 2004 32 1170 1177 10.1097/01.CCM.0000124875.98492.11 15190969 · DOI
  115. [116]Zhuo J.L. Li X.C. Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells J. Renin Angiotensin Aldosterone Syst. 2007 8 23 33 10.3317/jraas.2007.003 17487823 PMC2276849 · DOI
  116. [117]Suzuki Y. Ruiz-Ortega M. Lorenzo O. Ruperez M. Esteban V. Egido J. Inflammation and angiotensin II Int. J. Biochem. Cell Biol. 2003 35 881 900 10.1016/S1357-2725(02)00271-6 12676174 · DOI
  117. [118]Correa T.D. Jeger V. Pereira A.J. Takala J. Djafarzadeh S. Jakob S.M. Angiotensin II in septic shock: Effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis Crit. Care Med. 2014 42 e550 e559 10.1097/CCM.0000000000000397 24797374 · DOI
  118. [119]Cumming A.D. Kline R. Linton A.L. Association between renal and sympathetic responses to nonhypotensive systemic sepsis Crit. Care Med. 1988 16 1132 1137 10.1097/00003246-198811000-00010 3168506 · DOI
  119. [120]Laesser M. Oi Y. Ewert S. Fandriks L. Aneman A. The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model Acta Anaesthesiol. Scand. 2004 48 198 204 10.1111/j.0001-5172.2004.00283.x 14995942 · DOI
  120. [121]Nitescu N. Grimberg E. Guron G. Low-dose candesartan improves renal blood flow and kidney oxygen tension in rats with endotoxin-induced acute kidney dysfunction Shock 2008 30 166 172 10.1097/SHK.0b013e31815dd780 18091574 · DOI
  121. [122]Robertson A.L. Jr. Khairallah P.A. Angiotensin II: Rapid localization in nuclei of smooth and cardiac muscle Science 1971 172 1138 1139 10.1126/science.172.3988.1138 4324923 · DOI
  122. [123]Sirett N.E. McLean A.S. Bray J.J. Hubbard J.I. Distribution of angiotensin II receptors in rat brain Brain Res. 1977 122 299 312 10.1016/0006-8993(77)90296-7 189877 · DOI
  123. [124]Peters J. Kranzlin B. Schaeffer S. Zimmer J. Resch S. Bachmann S. Gretz N. Hackenthal E. Presence of renin within intramitochondrial dense bodies of the rat adrenal cortex Am. J. Physiol. 1996 271 E439 E450 10.1152/ajpendo.1996.271.3.E439 8843736 · DOI
  124. [125]Wanka H. Kessler N. Ellmer J. Endlich N. Peters B.S. Clausmeyer S. Peters J. Cytosolic renin is targeted to mitochondria and induces apoptosis in H9c2 rat cardiomyoblasts J. Cell. Mol. Med. 2009 13 2926 2937 10.1111/j.1582-4934.2008.00448.x 18671756 PMC4498947 · DOI
  125. [126]Kimura S. Zhang G.X. Nishiyama A. Shokoji T. Yao L. Fan Y.Y. Rahman M. Abe Y. Mitochondria-derived reactive oxygen species and vascular MAP kinases: Comparison of angiotensin II and diazoxide Hypertension 2005 45 438 444 10.1161/01.HYP.0000157169.27818.ae 15699441 · DOI
  126. [127]Duprez D.A. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review J. Hypertens. 2006 24 983 991 10.1097/01.hjh.0000226182.60321.69 16685192 · DOI
  127. [128]Ham K.R. Boldt D.W. McCurdy M.T. Busse L.W. Favory R. Gong M.N. Khanna A.K. Chock S.N. Zeng F. Chawla L.S. Sensitivity to angiotensin II dose in patients with vasodilatory shock: A prespecified analysis of the ATHOS-3 trial Ann. Intensive Care 2019 9 63 10.1186/s13613-019-0536-5 31161442 PMC6546778 · DOI
  128. [129]Wang W. Falk S.A. Jittikanont S. Gengaro P.E. Edelstein C.L. Schrier R.W. Protective effect of renal denervation on normotensive endotoxemia-induced acute renal failure in mice Am. J. Physiol. Ren. Physiol. 2002 283 F583 F587 10.1152/ajprenal.00270.2001 12167611 · DOI
  129. [132]Chawla L.S. Chen S. Bellomo R. Tidmarsh G.F. Angiotensin converting enzyme defects in shock: Implications for future therapy Crit. Care 2018 22 274 10.1186/s13054-018-2202-y 30368243 PMC6204272 · DOI
  130. [133]Lange M. Morelli A. Ertmer C. Broking K. Rehberg S. Van Aken H. Traber D.L. Westphal M. Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: Physiology and clinical implications Shock 2007 28 394 400 10.1097/shk.0b013e318050c836 17577137 · DOI
  131. [134]Zhang W. Chen X. Huang L. Lu N. Zhou L. Wu G. Chen Y. Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis Exp. Ther. Med. 2014 7 1342 1348 10.3892/etm.2014.1566 24940436 PMC3991516 · DOI
  132. [135]Chawla L.S. Busse L.W. Brasha-Mitchell E. Alotaibi Z. The use of angiotensin II in distributive shock Crit. Care 2016 20 137 10.1186/s13054-016-1306-5 27230465 PMC4882778 · DOI
  133. [136]Martineau D. Lamouche S. Briand R. Yamaguchi N. Functional involvement of angiotensin AT2 receptor in adrenal catecholamine secretion in vivo Can. J. Physiol. Pharmacol. 1999 77 367 374 10.1139/y99-037 10535686 · DOI
  134. [137]Wray G.M. Coakley J.H. Severe septic shock unresponsive to noradrenaline Lancet 1995 346 1604 10.1016/S0140-6736(95)91933-3 7500755 · DOI
  135. [138]Rhodes A. Evans L.E. Alhazzani W. Levy M.M. Antonelli M. Ferrer R. Kumar A. Sevransky J.E. Sprung C.L. Nunnally M.E. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Intensive Care Med. 2017 43 304 377 10.1007/s00134-017-4683-6 28101605 · DOI · Paper page
  136. [139]Scheeren T.W.L. Bakker J. De Backer D. Annane D. Asfar P. Boerma E.C. Cecconi M. Dubin A. Dunser M.W. Duranteau J. Current use of vasopressors in septic shock Ann. Intensive Care 2019 9 20 10.1186/s13613-019-0498-7 30701448 PMC6353977 · DOI
  137. [140]Khan Y.A. Spring J. Morales-Castro D. McCredie V.A. Novel Considerations in the Management of Shock. Vasopressors, Fluid Responsiveness, and Blood Pressure Targets Am. J. Respir. Crit. Care Med. 2019 199 1148 1150 10.1164/rccm.201804-0746RR 30817894 · DOI
  138. [141]Cohn J.N. Luria M.H. Studies in Clinical Shock and Hypotension. Ii. Hemodynamic Effects of Norepinephrine and Angiotensin J. Clin. Investig. 1965 44 1494 1504 10.1172/JCI105256 14332162 PMC292631 · DOI
  139. [142]Belle M.S. Jaffee R.J. The Use of Large Doses of Angiotensin in Acute Myocardial Infarction with Shock J. Lancet 1965 85 193 194 14290321
  140. [143]Del Greco F. Johnson D.C. Clinical experience with angiotensin II in the treatment of shock JAMA 1961 178 994 999 10.1001/jama.1961.03040490020005 13884972 · DOI
  141. [144]Derrick J.R. Anderson J.R. Roland B.J. Adjunctive use of a biologic pressor agent, angiotensin, in management of shock Circulation 1962 25 263 267 10.1161/01.CIR.25.1.263 13885617 · DOI
  142. [145]Antonucci E. Gleeson P.J. Annoni F. Agosta S. Orlando S. Taccone F.S. Velissaris D. Scolletta S. Angiotensin II in Refractory Septic Shock Shock 2017 47 560 566 10.1097/SHK.0000000000000807 27879559 · DOI
  143. [146]Thomas V.L. Nielsen M.S. Administration of angiotensin II in refractory septic shock Crit. Care Med. 1991 19 1084 1086 10.1097/00003246-199108000-00020 1860334 · DOI
  144. [147]Wakefield B.J. Sacha G.L. Khanna A.K. Vasodilatory shock in the ICU and the role of angiotensin II Curr. Opin. Crit. Care 2018 24 277 285 10.1097/MCC.0000000000000517 29877879 · DOI
  145. [148]Tumlin J.A. Murugan R. Deane A.M. Ostermann M. Busse L.W. Ham K.R. Kashani K. Szerlip H.M. Prowle J.R. Bihorac A. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II Crit. Care Med. 2018 46 949 957 10.1097/CCM.0000000000003092 29509568 PMC5959265 · DOI
  146. [149]Vincent J.L. Sakr Y. Sprung C.L. Ranieri V.M. Reinhart K. Gerlach H. Moreno R. Carlet J. Le Gall J.R. Payen D. Sepsis in European intensive care units: Results of the SOAP study Crit. Care Med. 2006 34 344 353 10.1097/01.CCM.0000194725.48928.3A 16424713 · DOI
  147. [150]Boyd J.H. Forbes J. Nakada T.A. Walley K.R. Russell J.A. Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality Crit. Care Med. 2011 39 259 265 10.1097/CCM.0b013e3181feeb15 20975548 · DOI · Paper page
  148. [151]Acheampong A. Vincent J.L. A positive fluid balance is an independent prognostic factor in patients with sepsis Crit. Care 2015 19 251 10.1186/s13054-015-0970-1 26073560 PMC4479078 · DOI
  149. [152]Hall A. Busse L.W. Ostermann M. Angiotensin in Critical Care Crit. Care 2018 22 69 10.1186/s13054-018-1995-z 29558991 PMC5861652 · DOI
  150. [153]Busse L.W. Wang X.S. Chalikonda D.M. Finkel K.W. Khanna A.K. Szerlip H.M. Yoo D. Dana S.L. Chawla L.S. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety Crit. Care Med. 2017 45 1285 1294 10.1097/CCM.0000000000002441 28489648 PMC5515638 · DOI
  151. [154]Senatore F. Jagadeesh G. Rose M. Pillai V.C. Hariharan S. Liu Q. McDowell T.Y. Sapru M.K. Southworth M.R. Stockbridge N. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock Am. J. Cardiovasc. Drugs 2019 19 11 20 10.1007/s40256-018-0297-9 30144016 · DOI
  152. [155]Salgado D.R. Rocco J.R. Silva E. Vincent J.L. Modulation of the renin-angiotensin-aldosterone system in sepsis: A new therapeutic approach? Expert Opin. Ther. Targets 2010 14 11 20 10.1517/14728220903460332 20001206 · DOI
  153. [156]Correa T.D. Filho R.R. Assuncao M.S. Silva E. Lima A. Vasodilators in Septic Shock Resuscitation: A Clinical Perspective Shock 2017 47 269 275 10.1097/SHK.0000000000000777 27787407 · DOI
  154. [157]Fernandes D. Pacheco L.K. Sordi R. Scheschowitsch K. Ramos G.C. Assreuy J. Angiotensin II receptor type 1 blockade improves hyporesponsiveness to vasopressors in septic shock Eur. J. Pharmacol. 2021 897 173953 10.1016/j.ejphar.2021.173953 33617825 · DOI
  155. [158]Hsu W.T. Galm B.P. Schrank G. Hsu T.C. Lee S.H. Park J.Y. Lee C.C. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality After Sepsis: A Population-Based Cohort Study Hypertension 2020 75 483 491 10.1161/HYPERTENSIONAHA.119.13197 31838905 · DOI
  156. [159]Lavoie J.L. Sigmund C.D. Minireview: Overview of the renin-angiotensin system--an endocrine and paracrine system Endocrinology 2003 144 2179 2183 10.1210/en.2003-0150 12746271 · DOI
  157. [160]Walley K.R. Sepsis-induced myocardial dysfunction Curr. Opin. Crit. Care 2018 24 292 299 10.1097/MCC.0000000000000507 29846206 · DOI · Paper page
  158. [161]Squara P. Hollenberg S. Payen D. Reconsidering Vasopressors for Cardiogenic Shock: Everything Should Be Made as Simple as Possible, but Not Simpler Chest 2019 156 392 401 10.1016/j.chest.2019.03.020 30935893 · DOI
  159. [162]Orfanos S.E. Chen X.L. Ryan J.W. Chung A.Y. Burch S.E. Catravas J.D. Assay of pulmonary microvascular endothelial angiotensin-converting enzyme in vivo: Comparison of three probes Toxicol. Appl. Pharmacol. 1994 124 99 111 10.1006/taap.1994.1013 8291066 · DOI
  160. [163]Cziraki A. Horvath I. Rubin J.W. Theodorakis M. Catravas J.D. Quantification of pulmonary capillary endothelium-bound angiotensin converting enzyme inhibition in man Gen. Pharmacol. 2000 35 213 218 10.1016/S0306-3623(01)00110-0 11827728 · DOI
  161. [164]Orfanos S.E. Armaganidis A. Glynos C. Psevdi E. Kaltsas P. Sarafidou P. Catravas J.D. Dafni U.G. Langleben D. Roussos C. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury Circulation 2000 102 2011 2018 10.1161/01.CIR.102.16.2011 11034953 · DOI
  162. [165]Pérez De Lema G. De Wit C. Cohen C.D. Nieto E. Molina A. Banas B. Luckow B. Vicente A.B. Mampaso F. Schlöndorff D. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice J. Pharmacol. Exp. Ther. 2003 307 275 281 10.1124/jpet.103.053678 12954793 · DOI
  163. [166]Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: Role of additional angiotensin II blockade Am. J. Physiol. Ren. Physiol. 2003 284 F863 F869 10.1152/ajprenal.00385.2002 12505865 · DOI
  164. [167]Hisada Y. Sugaya T. Tanaka S. Suzuki Y. Ra C. Kimura K. Fukamizu A. An essential role of angiotensin II receptor type 1a in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immune-mediated renal injury Lab. Investig. J. Tech. Methods Pathol. 2001 81 1243 1251 10.1038/labinvest.3780338 11555672 · DOI
  165. [168]Navar L.G. Kobori H. Prieto M.C. Gonzalez-Villalobos R.A. Intratubular renin-angiotensin system in hypertension Hypertension 2011 57 355 362 10.1161/HYPERTENSIONAHA.110.163519 21282552 PMC3073668 · DOI
  166. [169]Jurewicz M. McDermott D.H. Sechler J.M. Tinckam K. Takakura A. Carpenter C.B. Milford E. Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: Further mechanisms of angiotensin II-induced inflammation J. Am. Soc. Nephrol. JASN 2007 18 1093 1102 10.1681/ASN.2006070707 17329576 · DOI
  167. [170]Oberbarnscheidt M.H. Zecher D. Lakkis F.G. The innate immune system in transplantation Semin. Immunol. 2011 23 264 272 10.1016/j.smim.2011.06.006 21723740 PMC3535269 · DOI
  168. [171]Neilson E.G. The nephritogenic T lymphocyte response in interstitial nephritis Semin. Nephrol. 1993 13 496 502 8210812
  169. [172]Suzuki Y. Ruiz-Ortega M. Gomez-Guerrero C. Tomino Y. Egido J. Angiotensin II, the immune system and renal diseases: Another road for RAS? Nephrol. Dial. Transplant. 2003 18 1423 1426 10.1093/ndt/gfg223 12897073 · DOI
  170. [173]Rodríguez-Iturbe B. Pons H. Quiroz Y. Gordon K. Rincón J. Chávez M. Parra G. Herrera-Acosta J. Gómez-Garre D. Largo R. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure Kidney Int. 2001 59 2222 2232 10.1046/j.1523-1755.2001.00737.x 11380825 · DOI
  171. [174]Zambidis E.T. Park T.S. Yu W. Tam A. Levine M. Yuan X. Pryzhkova M. Péault B. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells Blood 2008 112 3601 3614 10.1182/blood-2008-03-144766 18728246 PMC2572789 · DOI
  172. [175]Shen X.Z. Billet S. Lin C. Okwan-Duodu D. Chen X. Lukacher A.E. Bernstein K.E. The carboxypeptidase ACE shapes the MHC class I peptide repertoire Nat. Immunol. 2011 12 1078 1085 10.1038/ni.2107 21964607 PMC3197883 · DOI
  173. [176]Thomas M.C. Pickering R.J. Tsorotes D. Koitka A. Sheehy K. Bernardi S. Toffoli B. Nguyen-Huu T.P. Head G.A. Fu Y. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse Circ. Res. 2010 107 888 897 10.1161/CIRCRESAHA.110.219279 20671240 · DOI
  174. [177]Al-Maghrebi M. Benter I.F. Diz D.I. Endogenous angiotensin-(1–7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats Pharmacol. Res. 2009 59 263 268 10.1016/j.phrs.2008.12.008 19166939 PMC2682227 · DOI
  175. [178]da Silveira K.D. Coelho F.M. Vieira A.T. Sachs D. Barroso L.C. Costa V.V. Bretas T.L. Bader M. de Sousa L.P. da Silva T.A. Anti-inflammatory effects of the activation of the angiotensin-(1–7) receptor, MAS, in experimental models of arthritis J. Immunol. (Baltim. Md. 1950) 2010 185 5569 5576 10.4049/jimmunol.1000314 20935211 · DOI
  176. [179]Crowley S.D. Rudemiller N.P. Immunologic Effects of the Renin-Angiotensin System J. Am. Soc. Nephrol. JASN 2017 28 1350 1361 10.1681/ASN.2016101066 28151411 PMC5407736 · DOI
  177. [180]Sampson A.K. Irvine J.C. Shihata W.A. Dragoljevic D. Lumsden N. Huet O. Barnes T. Unger T. Steckelings U.M. Jennings G.L. Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo Br. J. Pharmacol. 2016 173 729 740 10.1111/bph.13063 25560767 PMC4742292 · DOI
  178. [181]Mori D.N. Kreisel D. Fullerton J.N. Gilroy D.W. Goldstein D.R. Inflammatory triggers of acute rejection of organ allografts Immunol. Rev. 2014 258 132 144 10.1111/imr.12146 24517430 PMC3939032 · DOI
  179. [182]Fearon W.F. Okada K. Kobashigawa J.A. Kobayashi Y. Luikart H. Sana S. Daun T. Chmura S.A. Sinha S. Cohen G. Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation J. Am. Coll. Cardiol. 2017 69 2832 2841 10.1016/j.jacc.2017.03.598 28595700 PMC5546225 · DOI
  180. [183]Fildes J.E. Walker A.H. Keevil B. Hutchinson I.V. Leonard C.T. Yonan N. The effects of ACE inhibition on serum angiotensin II concentration following cardiac transplantation Transplant. Proc. 2005 37 4525 4527 10.1016/j.transproceed.2005.10.099 16387160 · DOI
  181. [184]Lorenz J.N. Chymase: The other ACE? Am. J. Physiol. Ren. Physiol. 2010 298 F35 F36 10.1152/ajprenal.00641.2009 19923404 PMC2806114 · DOI
  182. [185]Kovarik J.J. Kopecky C. Antlanger M. Domenig O. Kaltenecker C.C. Werzowa J. Hecking M. Mahr S. Grömmer M. Wallner C. Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. 2017 36 355 365 10.1016/j.healun.2016.08.022 27773450 · DOI
  183. [186]Urata H. Healy B. Stewart R.W. Bumpus F.M. Husain A. Angiotensin II-forming pathways in normal and failing human hearts Circ. Res. 1990 66 883 890 10.1161/01.RES.66.4.883 2156635 · DOI
  184. [188]Kovarik J.J. Kaltenecker C.C. Kopecky C. Domenig O. Antlanger M. Werzowa J. Eskandary F. Kain R. Poglitsch M. Schmaldienst S. Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation Sci. Rep. 2019 9 9762 10.1038/s41598-019-46114-x 31278281 PMC6611786 · DOI
  185. [189]Toto R.D. Transplantation: The role of RAAS blockade in kidney transplantation Nat. Rev. Nephrol. 2016 12 129 131 10.1038/nrneph.2015.201 26656455 PMC4760842 · DOI
  186. [190]Heinze G. Mitterbauer C. Regele H. Kramar R. Winkelmayer W.C. Curhan G.C. Oberbauer R. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation J. Am. Soc. Nephrol. JASN 2006 17 889 899 10.1681/ASN.2005090955 16481415 · DOI
  187. [191]Philipp T. Martinez F. Geiger H. Moulin B. Mourad G. Schmieder R. Lièvre M. Heemann U. Legendre C. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: Results from SECRET Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transplant. Assoc.-Eur. Ren. Assoc. 2010 25 967 976 10.1093/ndt/gfp581 19887503 · DOI
  188. [192]Knoll G.A. Fergusson D. Chassé M. Hebert P. Wells G. Tibbles L.A. Treleaven D. Holland D. White C. Muirhead N. Ramipril versus placebo in kidney transplant patients with proteinuria: A multicentre, double-blind, randomised controlled trial Lancet Diabetes Endocrinol. 2016 4 318 326 10.1016/S2213-8587(15)00368-X 26608067 · DOI

Cited by

Sorted by citations

Authors
Laghlam, D., Jozwiak, M., & Nguyen, L. S.
Affiliations
Clinique Ambroise Paré (FR)
Corresponding author
Nguyen, Lee S.
ORCID
Venue
Cells
Publisher
MDPI AG
Published
2021-07-13
Volume
10
Issue
7
Pages
1767
ISSN
2073-4409 (ISSN-L)
DOI
10.3390/cells10071767
PMC
PMC8303450
OpenAlex
W3178389255
Cited by
96
References
4
Citations by year
2026: 11 · 2025: 16 · 2024: 27 · 2023: 28 · 2022: 12 · 2021: 2
FWCI
3.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
renin-angiotensin system, immunomodulation, angiotensin II, angiotensin I, cancer, tumor angiogenesis, vasoplegic shock, organ rejection, solid organ transplantation, inflammation, fibrosis, blood pressure homeostasis
MeSH terms
Animals, Humans, Intensive Care Units, Neoplasms, Renin-Angiotensin System, Transplantation, Signal Transduction, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review